Financials data is unavailable for this security.
View more
Year on year Sonnet Biotherapeutics Holdings Inc had revenues fall -57.76% from 349.94k to 147.81k, though the company grew net income from a loss of 29.72m to a smaller loss of 18.83m.
| Gross margin | -- |
|---|---|
| Net profit margin | -14,287.67% |
| Operating margin | -14,271.32% |
| Return on assets | -100.88% |
|---|---|
| Return on equity | -264.57% |
| Return on investment | -255.30% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Sonnet Biotherapeutics Holdings Inc fell by 778.62k. Cash Flow from Financing totalled 21.01m or 14,211.81% of revenues. In addition the company used 21.34m for operations while cash used for investing totalled 443.25k.
| Cash flow per share | -16.48 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 4.01 |
|---|---|
| Tangible book value per share | 4.01 |
More ▼
Balance sheet in USDView more
| Current ratio | 1.65 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
